


# Disorders of Bile Acid Metabolism and their Diagnosis

Claire Hart


Department of Clinical Chemistry

Sheffield Children's Hospital

# What is a Bile Acid?




Cholic Acid  
(3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$  trihydroxycholanoate)




Chenodeoxycholic Acid  
(3 $\alpha$ , 7 $\alpha$  dihydroxycholanoate)

# What is Ursodeoxycholic acid?




Chenodeoxycholic Acid  
(3 $\alpha$ , 7 $\alpha$  -dihydroxycholanoate)




Ursodeoxycholic Acid  
(3 $\alpha$ , 7 $\beta$  -dihydroxycholanoate)

# What is a Bile Salt?


Glyco or Tauro conjugate of cholic or chenodeoxycholic acid




Glycocholic acid



Glycochenodeoxycholic acid




Taurocholic acid



Taurochenodeoxycholic acid


# How do we make Bile Acids / Salts?

“Acidic Pathway”  
( $<1$  yr of age)



Cholesterol

Bile Acids are made predominantly in the liver using cholesterol as the precursor. Bile Salts provide negative feedback inhibiting the pathway at cholesterol 7 $\alpha$  hydroxylase (1)



# What are the disorders of Bile Acid /Salt Metabolism?

- Bile Acid synthesis disorders – single gene defects in the synthesis of cholic and chenodeoxycholic acid from cholesterol
  - Oxysterol 7 alpha hydroxylase deficiency (CYP7B1)
  - 3-beta-hydroxy-delta<sup>5</sup>-C27-steroid oxidoreductase deficiency (HSD3B7)
  - Delta<sup>4</sup>-3-oxosteroid 5 beta reductase deficiency (AKR1D1)
- Typically present with prolonged neonatal jaundice, steatorrhea, treatment resistant diarrhoea, fat soluble vitamin deficiencies (rickets, haemorrhage), pruritus, - progressing to cirrhosis / liver failure. Of note patients have a normal gamma GT
- Oxysterol 7 alpha hydroxylase deficiency may also present with hereditary spastic paraplegia (onset from childhood to adulthood)

# What are the disorders of Bile Acid / Salt Metabolism?

- Cerebrotendinous Xanthomatosis / Sterol 27-hydroxylase deficiency (CYP27A1)
- Technically a bile acid synthesis disorder but usually put in category of own
- Presents with; self-limiting neonatal hepatitis (occasionally persists and progresses to cholestatic liver disease), treatment resistant diarrhoea, cataract, -and from 2<sup>nd</sup> decade onwards-xanthomas, atherosclerosis, osteoporosis, progressive ataxia and eventually dementia

# What are the disorders of Bile Acid /Salt Metabolism?


- Bile Acid Amidation (conjugation) defects –failure to conjugate bile acids to taurine or glycine to form the active Bile Salts
  - Bile Acid-CoA:aminoacid N-acyltransferase deficiency (BAAT)
  - Bile Acid-CoA ligase deficiency (SLC27A5)
- N-acyltransferase deficiency typically presents with failure to thrive, cholestatic liver disease, fat soluble vitamin deficiency
- Ligase deficiency is of uncertain clinical significance



# What are the disorders of Bile Acid / Salt Metabolism?

- Peroxisomal Disorders – several stages of bile acid synthesis occur in the peroxisome so peroxisomal biogenesis disorders and some single enzyme defects impact bile acid synthesis
  - Peroxisomal Biogenesis disorders (PEX genes)
  - D-bifunctional protein deficiency (HSD17B4)
  - 2-Methylacyl-CoA racemase deficiency (AMACR)
  - Sterol carrier protein-2 (SCP2)
- All have a specific pattern of metabolite(s), although the pattern may not be observable in “milder” patients (good specificity, less good sensitivity)

# Peroxisomal Bile Acid Metabolism



# Differential Diagnosis of Peroxisomal Disorders Using Bile Acids



Disorder	VLCFA	Phytanate	Pristanate	Bile Acid metabolites
Peroxisomal Biogenesis Disorders	↑↑	↑*	↑*	Taurotrihydroxycholestanoate (m/z 556) + Taurotetrahydroxycholestanoate (m/z 572)
D-bifunctional protein deficiency	↑(↑)	↑*	↑*	Taurotrihydroxycholestenoate (m/z 554) + Taurotetrahydroxycholestenoate (m/z 570)
Methylacyl-CoA racemase def	N	N	↑	Taurotrihydroxycholestanoate (m/z 556)
Sterol Carrier protein X	N or sl ↑	N	↑	Variety of urine bile alcohol glucuronides (some overlap with CTX)

\* Dependent on dietary intake, often not elevated in neonates


# What are not disorders of Bile Acid /Salt Metabolism?

- Progressive Familial Intrahepatic Cholestasis (PFIC) disorders
  - Several different disorders of bile salt TRANSPORT
  - Present with jaundice, pruritus, hepatosplenomegaly, cirrhosis
  - Present with generalised increase in the 4 primary bile salts (cholestasis) but no distinguishing metabolites present
  - Therefore cannot differentiate between the PFIC disorders and cholestasis of other cause


# How do we make Bile Salts?




CTX



Oxysterol 7 $\alpha$  hydroxylase deficiency



3 $\beta$ -hydroxy-delta5-C27-oxidoreductase deficiency



Delta4-3-oxosteroid 5 beta- reductase deficiency



Alpha-methyl-acyl-CoA racemase deficiency



Peroxisomal Biogenesis disorders and D-bifunctional protein deficiency



Bile Amidation defects

# Analysis of Bile Acids /Salts

- ESI-MS/MS in negative ion mode ( $M-H^-$  ions)
- Direct injection (no column)
- Scan across range 300-700 m/z
- 3 x “Parents of” scans
  - Parents of 74 = Glyco conjugates
  - Parents of 80 = Tauro conjugates
  - Parents of 97 = Sulpho conjugates
- Use D4-Taurotrihydroxycholanoate as internal standard for all species
- Calibration curves using glyco- and tauro- di and trihydroxycholanoate (4 primary bile salts)

# Sample Preparation (Urine and Plasma)

- 50 $\mu$ l sample + 50 $\mu$ l of D4- Taurocholic acid internal standard (in acetonitrile) + 250 $\mu$ l acetonitrile
- Vortex mixed, centrifuged and supernatant transferred to multiwell plate
- Running buffer 1:1 acetonitrile / water

# Report Format

- Report Quantitative Results for 4 Primary bile salts (with reference ranges) + qualitative report on the presence or absence of any abnormal bile acid metabolites

## Bile Acid Analysis by Electrospray - Mass Spectrometry


Glycodihydroxycholanoate	2	µmol/L	<6
Glycotrihydroxycholanoate	1	µmol/L	<2
Taurodihydroxycholanoate	1	µmol/L	<2
Taurotrihydroxycholanoate	<1	µmol/L	<2

Normal concentration of primary bile salts.


No abnormal conjugates of bile acid intermediates were detected, which tends to exclude disorders of bile acid biosynthesis.




# Normal Plasma Profile




# Cholestasis (PFIC 2 patient)




# Cerebrotendinous Xanthomatosis



# Delta<sup>4</sup>-3-oxosteroid 5 beta reductase deficiency (AKR1D1)







# 3-beta-hydroxy-delta<sup>5</sup>-C27-steroid oxidoreductase deficiency (HSD3B7)




# Bile Amidation / Conjugation Defect

Chenodeoxycholic acid


Cholic acid



# Peroxisomal Biogenesis Disorder



# D-Bifunctional Protein Deficiency





# Urine or Plasma or Both?

- Urine definitely more sensitive for CTX and Sterol carrier protein X (glucuronides are very water soluble)
- Plasma seems to be better for Peroxisomal disorders generally
- For other disorders it seems to be variable depending on patient but often it is the same difference
- Overall the answer is “it depends” – generally it is a good idea to send both if at all possible

# Diagnostic Problem 1:

## Patients already treated with Ursodeoxycholic acid

- Ursodeoxycholic acid and Chenodeoxycholic acid are isobaric stereoisomers (both dihydroxycholanoate) - cannot distinguish between them by this method
- Therefore if patient treated with Urso may falsely elevate glyco and / or tauro-dihydroxycholanoate
- Patients with bile acid synthesis disorders should typically have low / low normal bile acids – but if they have been treated you will produce a cholestatic picture that can confuse things

## Diagnostic Problem 2:

### Secondary increase in abnormal metabolites due to underlying liver disease / hepatic viruses

- Not uncommon to see secondary increases in sulpho and glycohydroxycholenoate (Oxysterol 7-alpha hydroxylase deficiency metabolites) – usually seen in cholestatic patients (all causes), immaturity probably also a factor
- Sometimes see secondary increases in glyco and tauro di and trihydroxy-3-oxo-4-cholenoate compounds (5beta reductase, AKR1D1 metabolites) – associated with hepatic viruses and haemochromatosis
- In theory primary patients should be clear as primary bile acids will be low or low normal, whereas in secondary patients they will be high - however if a primary patient has been given ursodeoxycholic acid already you can get a very confused picture
- Have to go by relative peak heights (are abnormal metabolites substantially bigger than primary bile acid peaks)

# **Diagnostic Problem 3:**

## **Very rare disorders!**

- Other than CTX and PBD –these disorders are VERY rare
- Makes it difficult to build up experience of diagnosing them

# Treatment

- CTX and other primary bile acid synthesis disorders require treatment with cholic and / or chenodeoxycholic acid
- These can be converted to their tauro and glyco conjugates in liver (with exception of amidation defects) and will down regulate cholesterol-7-alpha hydroxylase and avoid build up of toxic intermediates
- Ursodeoxycholic acid doesn't work (doesn't down regulate)
- Liver transplant may be necessary
- Glycocholic acid used to treat amidation defects

# Useful review papers



ELSEVIER

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)



Biochimica et Biophysica Acta 1763 (2006) 1427–1440



[www.elsevier.com/locate/bbamcr](http://www.elsevier.com/locate/bbamcr)

Review

## Peroxisomes and bile acid biosynthesis

Sacha Ferdinandusse\*, Sander M. Houten

*Laboratory Genetic Metabolic Diseases, Departments of Clinical Chemistry and Pediatrics, F0-224 Academic Medical Center at the University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands*

Received 28 April 2006; received in revised form 24 August 2006; accepted 1 September 2006  
Available online 14 September 2006

J Inherit Metab Dis (2011) 34:593–604  
DOI 10.1007/s10545-010-9259-3

SSIEM SYMPOSIUM 2010

## Disorders of bile acid synthesis

Peter Theodore Clayton